The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer (Q27684613)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer	scientific article

Statements

scholarly article

0 references

The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer (English)

0 references

author name string

Ulrich Lücking

1

0 references

Rolf Jautelat

2

0 references

Martin Krüger

3

0 references

Thomas Brumby

4

0 references

Philip Lienau

5

0 references

Martina Schäfer

6

0 references

Hans Briem

7

0 references

Julia Schulze

8

0 references

Alexander Hillisch

9

0 references

Andreas Reichel

10

0 references

Antje Margret Wengner

11

0 references

Gerhard Siemeister

12

0 references

publication date

July 2013

0 references

0 references

8

0 references

7

0 references

1067-85

0 references

Novel potent pharmacological cyclin-dependent kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Cell cycle kinases as therapeutic targets for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Cyclin D as a therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Rendezvous in chemical space? Comparing the small molecule compound libraries of Bayer and Schering

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamide-two heads are better than one?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Action of nitrogen trichloride on proteins; progress in the isolation of the toxic factor.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Water-soluble prodrugs of an Aurora kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Perfluoroalkylation with Organosilicon Reagents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

A fast flexible docking method using an incremental construction algorithm.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase II influence inhibitor binding constants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

AMoRe: an automated package for molecular replacement

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Macromolecular TLS refinement in REFMAC at moderate resolutions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Rhodium-Catalyzed Imination of Sulfoxides and Sulfides: Efficient Preparation of N-Unsubstituted Sulfoximines and Sulfilimines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

21 January 2018

Time course and disposition of methazolamide in human plasma and red blood cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d t

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

7 January 2021

based on heuristic

inferred from DOI database lookup

L-S,R-buthionine sulfoximine: historical development and clinical issues

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

7 January 2021

based on heuristic

inferred from DOI database lookup

The Catalytic Versatility of Erythrocyte Carbonic Anhydrase. III. Kinetic Studies of the Enzyme-Catalyzed Hydrolysis of p-Nitrophenyl Acetate*

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300096

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CMDC.201300096

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27684613&oldid=1639563876"